Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

PURPOSE: Glioblastoma represents the most common primary brain tumor. Although antiangiogenics are used in the recurrent setting, they do not prolong survival. Glioblastoma is known to upregulate fatty acid synthase (FASN) to facilitate lipid biosynthesis. TVB-2640, a FASN inhibitor, impairs this ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, William, Diaz Duque, Adolfo Enrique, Michalek, Joel, Konkel, Brandon, Caflisch, Laura, Chen, Yidong, Pathuri, Sarath Chand, Madhusudanannair-Kunnuparampil, Vinu, Floyd, John, Brenner, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320469/
https://www.ncbi.nlm.nih.gov/pubmed/37093199
http://dx.doi.org/10.1158/1078-0432.CCR-22-2807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320469/
https://www.ncbi.nlm.nih.gov/pubmed/37093199
http://dx.doi.org/10.1158/1078-0432.CCR-22-2807

Ejemplares similares